8-K: HeartSciences Designates New Series D Preferred Stock to Facilitate $15 Million Capital Raise

HeartSciences Inc. has officially designated 4,285,714 shares of Series D Convertible Preferred Stock, a key step in its previously announced offering to raise up to $15 million.

Summary

• HeartSciences Inc. filed an 8-K to announce the designation of 4,285,714 shares of Series D Convertible Preferred Stock, par value $0.001 per share.
• This designation is in connection with a previously disclosed offering of up to 4,285,714 units at an offering price of $3.50 per unit, aiming for a maximum of $15,000,000.
• Each unit in the offering consists of one share of Series D Convertible Preferred Stock and one warrant to purchase one share of the company's common stock at an exercise price of $5.00 per share.
• The Series D Preferred Stock is convertible into one share of Common Stock at the option of the holder at any time.
• The company retains the right to force conversion of the Series D Preferred Stock if the Common Shares' closing sale price is at or above $5.00 for 10 consecutive trading days, upon a Change in Control, or if the company completes a firm commitment public offering generating gross proceeds of at least $15,000,000 at a price of $5.00 or more per share.
• The Series D Preferred Stock is non-cumulative regarding dividends, perpetual, non-maturing, non-redeemable, and not subject to a sinking fund.
• In the event of liquidation, holders of Series D Preferred Stock are entitled to receive $3.50 per share plus any declared but unpaid dividends, prior to any distributions to holders of junior securities.
• The Series D Preferred Stock ranks senior to Common Stock but junior to the company's Series C Preferred Shares.
• Series D Preferred Stock has limited voting rights, primarily requiring affirmative vote for amendments materially and adversely affecting its rights, preferences, or voting power, or certain corporate transactions like mergers.

Sentiment

Score: 6

Explanation: The designation of preferred stock for a capital raise is a neutral to slightly positive event, as it provides a mechanism for funding. However, it introduces potential future dilution for common shareholders and establishes a liquidation preference, which are considerations for existing equity holders.

Positives

• The designation of Series D Preferred Stock facilitates a capital raise of up to $15,000,000, providing the company with potential funding for operations and activities.
• The structure of the offering, combining preferred stock with warrants, may appeal to a broader range of investors.
• The company retains the option for forced conversion under specific conditions (e.g., common stock price reaching $5.00, Change in Control, or a significant public offering), which could simplify the capital structure in the future.

Negatives

• The issuance of convertible preferred stock and warrants introduces potential future dilution for existing common shareholders upon conversion and exercise.
• Series D Preferred Stock holders have a liquidation preference of $3.50 per share over common shareholders, meaning common shareholders would receive distributions only after preferred holders are paid in a liquidation event.
• The Series D Preferred Stock is junior to the Series C Preferred Shares, indicating a tiered preference structure.

Risks

• Potential dilution of common stock value upon the conversion of Series D Preferred Stock into common shares and the exercise of associated warrants.
• In a liquidation, dissolution, or winding up of the Corporation, holders of Series D Preferred Stock have a preferential right to receive $3.50 per share plus declared but unpaid dividends before any distribution to common shareholders.
• The company's ability to force conversion is contingent on the common stock price reaching $5.00 per share for 10 consecutive trading days, which is subject to market volatility and may not occur.
• The Series D Preferred Stock is explicitly ranked junior to the Corporation's Series C Preferred Shares, meaning Series C holders have priority in dividend payments and asset distribution upon liquidation.

Future Outlook

The document primarily details the terms of a new class of preferred stock and does not provide a general future outlook for the company's operations or financial performance, beyond facilitating a capital raise.

Management Comments

• Andrew Simpson, Chief Executive Officer of HeartSciences Inc., certified the Certificate of Designation.
• Andrew Simpson, President, Chief Executive Officer and Chairman of the Board of Directors, signed the 8-K filing.

Industry Context

The designation of convertible preferred stock and associated warrants is a common strategy for companies, particularly those in the growth phase or seeking to raise capital, to attract investors with different risk appetites than common stock investors. This mechanism allows the company to secure funding while offering potential upside through conversion rights and warrants, often used when traditional debt or common equity financing might be less favorable.

Corporate Governance

Legal Proceedings

• The Certificate of Designation includes a provision that any dispute arising under or related to the agreement shall be settled by binding arbitration through Judicial Arbitration and Mediation Services (JAMS) in Dallas, Texas, with a waiver of jury trial rights.

Stakeholder Impact

• **Shareholders (Common Stock)**: Face potential future dilution from the conversion of Series D Preferred Stock and the exercise of warrants. Their claims are subordinated to Series D holders in a liquidation scenario.
• **Investors (Series D Preferred Stock)**: Gain a liquidation preference and the option to convert into common stock, offering a structured investment with potential equity upside. They also have specific protective voting rights.
• **Company (HeartSciences Inc.)**: Gains a mechanism to raise up to $15 million in capital, which can fund operations and growth initiatives. The forced conversion option provides flexibility in managing the capital structure.

Next Steps

• Upon approval of the Certificate of Designations by the Texas Secretary of State, the Company shall submit a subsequent Current Report on Form 8-K to the SEC.
• Proceed with the previously announced offering of units to raise capital.

Key Dates

Keywords

HeartSciences, HSCS, Series D Convertible Preferred Stock, Preferred Stock, Warrants, Capital Raise, SEC Filing, 8-K, Equity Financing, Dilution, Liquidation Preference, Convertible Securities, Corporate Governance